Pharmaceutical Cost Transparency

Act 220 of the 2017 Legislature requires drug manufacturers marketing their drugs to Louisiana to report wholesale acquisition cost information to the Board on a quarterly basis.  Until the Board has developed the web portal which manufacturers will use to report their information, the Board has established a reporting procedure for the interim reports.  The Pharmaceutical Cost Transparency document is available here as well as in the Guidance Documents section in the Public Library.